Page last updated: 2024-11-13
bay 85-3934
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 59603622 |
| CHEMBL ID | 3646118 |
| SCHEMBL ID | 6114312 |
| SCHEMBL ID | 2569970 |
| MeSH ID | M000613289 |
Synonyms (52)
| Synonym |
|---|
| molidustat [usan:inn] |
| 1154028-82-6 |
| 9jh486cz13 , |
| unii-9jh486cz13 |
| molidustat [usan] |
| 2-(6-(morpholin-4-yl)pyrimidin-4-yl)-4-(1h-1,2,3-triazol-1-yl)-1,2-dihydro-3h-pyrazol-3-one |
| molidustat , |
| molidustat [inn] |
| who 9655 |
| bay 85-3934 |
| IJMBOKOTALXLKS-UHFFFAOYSA-N , |
| 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1h-1,2,3-triazol-1-yl)-1,2-dihydro-3h-pyrazol-3-one |
| molidustat [who-dd] |
| 3h-pyrazol-3-one, 1,2-dihydro-2-(6-(4-morpholinyl)-4-pyrimidinyl)-4-(1h-1,2,3-triazol-1-yl)- |
| bay-85-3934 |
| bdbm118339 |
| us8653111, 72 |
| SCHEMBL6114312 |
| SCHEMBL2569970 |
| AC-35448 |
| bay85-3934 |
| bay-853934 |
| 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1h-pyrazol-3-one |
| gtpl8456 |
| HY-12654 |
| CHEMBL3646118 |
| DTXSID80151089 , |
| AKOS026750584 |
| EX-A562 |
| molidustat(bay85-3934) |
| 2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1h-1,2,3-triazol-1-yl)-1,2-dihydro-3h-pyrazol-3-one |
| AS-74456 |
| 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-2,3-dihydro-1h-pyrazol-3-one |
| 2-(6-morpholinopyrimidin-4-yl)-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-3(2h)-one |
| mfcd28411428 |
| NCGC00388364-04 |
| 3h-pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1h-1,2,3-triazol-1-yl)- |
| molidustat(bay 85-3934) |
| 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)-1~{h}-pyrazol-3-one |
| a1h , |
| molidustat (bay 85-3934) |
| S8138 |
| Q27087553 |
| BCP14477 |
| molidustat;bay 85-3934;bay-85-3934; bay 853934; bay-853934; bay853934 |
| 1-(6-morpholinopyrimidin-4-yl)-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-ol |
| SB17156 |
| CCG-267626 |
| 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol |
| qeq , |
| molidustatum |
| dtxcid0073580 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The primary efficacy variable for both studies was change in blood hemoglobin (Hb) level from baseline to each post-baseline visit, and safety outcomes included adverse events (AEs)." | ( Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M, 2019) | 0.51 |
| " The safety outcomes included evaluation of all adverse events." | ( Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Yamamoto, H, 2021) | 0.62 |
| " The proportion of patients who reported at least 1 treatment-emergent adverse event (TEAE) was 93." | ( Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Yamamoto, H, 2021) | 0.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Herein we describe the discovery, synthesis, structure-activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia." | ( Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. Akbaba, M; Beck, H; Ergüden, JK; Flamme, I; Hartung, IV; Jeske, M; Karig, G; Keldenich, J; Militzer, HC; Oehme, F; Stoll, F; Thede, K; Thuss, U, 2018) | 0.48 |
| " Study 2 investigated the absolute bioavailability and pharmacodynamics of molidustat (part 1, n = 12; part 2, n = 16)." | ( Absorption, distribution, metabolism and excretion of molidustat in healthy participants. Gerisch, M; Kaiser, A; Kern, A; Lentini, S; Matsuno, K; Thuss, U; van der Mey, D, 2020) | 0.56 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In repeat oral dosing of BAY 85-3934, hemoglobin levels were increased compared with animals that received vehicle, while endogenous EPO remained within the normal physiological range." | ( Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. Ellinghaus, P; Flamme, I; Jeske, M; Keldenich, J; Oehme, F; Thuss, U, 2014) | 0.96 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 2.9411 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 2.9411 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prolyl 4-hydroxylase | Paramecium bursaria Chlorella virus 1 | IC50 (µMol) | 26.8000 | 5.0000 | 6.2667 | 8.5000 | AID1543452 |
| Prolyl 4-hydroxylase | Paramecium bursaria Chlorella virus 1 | Ki | 16.0500 | 1.0700 | 2.1750 | 3.2800 | AID1543452 |
| Prolyl 3-hydroxylase OGFOD1 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 1.0000 | 1.0000 | 1.0000 | AID1543455 |
| Prolyl hydroxylase EGLN2 | Homo sapiens (human) | IC50 (µMol) | 0.4800 | 0.4800 | 1.4044 | 2.1000 | AID1354514 |
| Egl nine homolog 1 | Homo sapiens (human) | IC50 (µMol) | 0.2901 | 0.0070 | 1.8614 | 8.0000 | AID1280627; AID1280630; AID1354515; AID1543453; AID1916161 |
| Prolyl hydroxylase EGLN3 | Homo sapiens (human) | IC50 (µMol) | 0.4500 | 0.4500 | 0.4500 | 0.4500 | AID1354516 |
| Hypoxia-inducible factor 1-alpha inhibitor | Homo sapiens (human) | IC50 (µMol) | 48.5000 | 8.6000 | 8.6000 | 8.6000 | AID1543454; AID1916162 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (63)
Molecular Functions (25)
Ceullar Components (11)
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1543455 | Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Inhibition of a viral prolyl hydroxylase. |
| AID1280630 | Inhibition of PHD2 (unknown origin) using biotinylated HIF-1alpha (558 to 574 residues) as substrate after 1 hr by homogeneous time-resolved fluorescence assay | 2015 | ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12 | Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. |
| AID1354521 | In vivo inhibition of PHD in Wistar rat assessed as increase in packed cell volume at 5 mg/kg, po measured after 26 days relative to control | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1354516 | Inhibition of recombinant human HIF-PHD3 expressed in baculovirus-infected Sf9 cells using biotin labelled DLDLEMLAPYIPMDDDFQL as substrate preincubated for 60 mins followed by substrate addition measured after 60 mins by TR-FRET assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1354520 | In vivo inhibition of PHD in Wistar rat assessed as increase in packed cell volume at 1.25 mg/kg, po measured after 26 days relative to control | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1543452 | Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Inhibition of a viral prolyl hydroxylase. |
| AID1354519 | Oral bioavailability in monkey | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1916162 | Inhibition of FIH (unknown origin) by solid-phase extraction coupled to MS based assay | 2021 | Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11 | Inhibition of the Oxygen-Sensing Asparaginyl Hydroxylase Factor Inhibiting Hypoxia-Inducible Factor: A Potential Hypoxia Response Modulating Strategy. |
| AID1916161 | Inhibition of N-terminal His tagged PHD2 (181 to 426 residues) (unknown origin) measured by MALDI-TOF MS analysis | 2021 | Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11 | Inhibition of the Oxygen-Sensing Asparaginyl Hydroxylase Factor Inhibiting Hypoxia-Inducible Factor: A Potential Hypoxia Response Modulating Strategy. |
| AID1280627 | Displacement of FITC-HIF-1alpha (556 to 574 residues) from PHD2 (181 to 426 residues) (unknown origin) after 60 mins by fluorescence polarization assay | 2015 | ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12 | Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. |
| AID1354517 | Oral bioavailability in Wistar rat | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1354518 | Oral bioavailability in dog | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1543454 | Inhibition of recombinant human FIH using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by LC-MS analysis | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Inhibition of a viral prolyl hydroxylase. |
| AID1354514 | Inhibition of recombinant human HIF-PHD1 expressed in baculovirus-infected Sf9 cells using biotin labelled DLDLEMLAPYIPMDDDFQL as substrate preincubated for 60 mins followed by substrate addition measured after 60 mins by TR-FRET assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1354515 | Inhibition of recombinant human HIF-PHD2 expressed in baculovirus-infected Sf9 cells using biotin labelled DLDLEMLAPYIPMDDDFQL as substrate preincubated for 60 mins followed by substrate addition measured after 60 mins by TR-FRET assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. |
| AID1543453 | Inhibition of recombinant human PHD2 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by LC-MS analysis | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Inhibition of a viral prolyl hydroxylase. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (37)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (40.54) | 24.3611 |
| 2020's | 22 (59.46) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.48) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 11 (29.73%) | 5.53% |
| Reviews | 4 (10.81%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (59.46%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||